Jeff Katstra

Jeff Katstra is a seasoned professional in the pharmaceutical and biotechnology sectors, currently serving as VP and Head of CMC and Pharmaceutical Development at Galectin Therapeutics since June 2023. Previously, Jeff held the position of Head of Development at Syntis Bio for a brief period and served as Senior Director at Lyndra Therapeutics from September 2019 to August 2022. Jeff's extensive experience includes roles at Agios Pharmaceuticals as Director and Associate Director, and a significant tenure at Vertex Pharmaceuticals where Jeff progressed from Scientist I to Scientific Fellow I. Early career experience encompasses roles as Senior Scientist at Pulmatrix Inc., Research Scientist at Harvard University, and Research Engineer II at Advanced Inhalation Research/Alkermes. Jeff holds a Master of Science in Biomedical Engineering and a Bachelor's degree in Mechanical Engineering, both from the University of Michigan.